v3.26.1
Condensed Consolidated Statements of Operations - USD ($)
3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Operating expenses:    
Research and development $ 1,782,300 $ 1,941,680
General and administrative 1,102,538 1,084,828
Total operating expenses 2,884,838 3,026,508
Loss from operations (2,884,838) (3,026,508)
Other income (expense):    
Foreign currency transaction loss (1,516) (788)
Interest income, net 61,389 76,028
Total other income 59,873 75,240
Net loss applicable to common stockholders $ (2,824,965) $ (2,951,268)
Basic net loss per share (in Dollars per share) $ (0.28) $ (0.97)
Diluted net loss per share (in Dollars per share) $ (0.28) $ (0.97)
Basic weighted average common shares outstanding (in Shares) 10,164,898 3,049,625
Diluted weighted average common shares outstanding (in Shares) 10,164,898 3,049,625